Crossroads in GDNF therapy for Parkinson's disease

The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society

[1]  J. Kordower,et al.  Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates , 2006, Gene Therapy.

[2]  D. Brooks,et al.  Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain , 2005, Nature Medicine.

[3]  S. Gill,et al.  Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study , 2005, Annals of neurology.

[4]  G. Gerhardt,et al.  Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. , 2005, Journal of neurosurgery.

[5]  M. Schulzer,et al.  Placebo mechanisms and reward circuitry: clues from Parkinson's disease , 2004, Biological Psychiatry.

[6]  J. Bloch,et al.  Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons , 2004, Neurobiology of Disease.

[7]  Luana Colloca,et al.  Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus , 2004, Nature Neuroscience.

[8]  T. Laessig,et al.  The p75 Neurotrophin Receptor Can Induce Autophagy and Death of Cerebellar Purkinje Neurons , 2004, The Journal of Neuroscience.

[9]  J. Obeso,et al.  Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough , 2004, The Lancet Neurology.

[10]  D. Russell,et al.  Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. , 2004, Archives of general psychiatry.

[11]  David Eidelberg,et al.  The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson’s disease and multiple system atrophy , 2004, Clinical Autonomic Research.

[12]  A. Vortmeyer,et al.  Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. , 2003, Journal of neurosurgery.

[13]  C. Goetz,et al.  Impact of placebo assignment in clinical trials of Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[14]  Vesna Sossi,et al.  A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.

[15]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[16]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[17]  H. Schellekens.  Relationship between biopharmaceutical immunogenicity of epoetin alfa and pure red cell aplasia , 2003, Current medical research and opinion.

[18]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[19]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[20]  Heidi Phillips,et al.  Heparin Coinfusion during Convection-Enhanced Delivery (CED) Increases the Distribution of the Glial-Derived Neurotrophic Factor (GDNF) Ligand Family in Rat Striatum and Enhances the Pharmacological Activity of Neurturin , 2001, Experimental Neurology.

[21]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[22]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[23]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.